You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Chemistry
Early Stage: Hit-to-Lead
The initial step in bringing a target compound to market involves identifying small molecule hits using various paradigm. These hits are then further developed and optimized to identify promising lead compounds.
Services we provide include:
- Analysis of high throughput screening (HTS) or virtual screening/assay results, including preliminary structure-activity relationship (SAR) evaluation, physical-chemical properties, identifying hit clusters, etc.
- Risk assessment, including structural liabilities and PAINS analysis
- Triage of hits generated through AI tools, and recommend targets for synthesis
- Hit confirmation: resynthesis/purification for confirming the structure and activity of hits
- Hit expansion by synthesis of selected analogs to evaluate scaffolds and explore basic SAR
- Preliminary assessment of ADME profile
- Select lead series (3-5 series) based on SAR and ADME results
Learn more about